Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
| Autor: | Eric J, Lawitz, Bal Raj, Bhandari, Peter J, Ruane, Anita, Kohli, Eliza, Harting, Dora, Ding, Jen-Chieh, Chuang, Ryan S, Huss, Chuhan, Chung, Robert P, Myers, Rohit, Loomba |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Liver Cirrhosis
Hypertriglyceridemia Peroxisome Proliferator-Activated Receptor-α Hepatology Nonalcoholic Fatty Liver Disease Gastroenterology & Hepatology Liver Disease Clinical Sciences Gastroenterology Evaluation of treatments and therapeutic interventions Hepatitis Fenofibrate Non-alcoholic Fatty Liver Disease 6.1 Pharmaceuticals Humans Very Low Density Lipoprotein Digestive Diseases Triglycerides Acetyl-CoA Carboxylase Hypolipidemic Agents |
| Zdroj: | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 21, iss 1 |
| Popis: | Background & aimsPatients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) are at high risk of morbidity and mortality. We previously found that a combination of the farnesoid X receptor agonist cilofexor (CILO) and the acetyl-CoA carboxylase inhibitor firsocostat (FIR) improved liver histology and biomarkers in NASH with advanced fibrosis but was associated with hypertriglyceridemia. We evaluated the safety and efficacy of icosapent ethyl (Vascepa) and fenofibrate to mitigate triglyceride elevations in patients with NASH treated with CILO and FIR.MethodsPatients with NASH with elevated triglycerides (≥150 and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|